Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

G T Verhoeven, J P J Hegmans, P G H Mulder, J M Bogaard, H C Hoogsteden, J-B Prins

Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPD patients with bronchial hyperresponsiveness (BHR).

Methods: Twenty-three patients with COPD were studied. Patients had to be persistent current smokers between 40 and 70 years of age. Non-specific BHR was defined as a PC_{20} for histamine of <8 mg/ml. Patients received either 2 × 500 µg FP or placebo for 6 months. Expiratory volumes were measured at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from asymptomatic smokers served as controls.

Results: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP. Forced expiratory volume in 1 second (FEV1) showed a steep decline in the placebo group but remained stable in patients treated with FP. FEV1/FVC, and maximal expiratory flows at 50% and 25% FVC (MEF_{50}, MEF_{25}) were significantly increased in the FP treated patients compared with the placebo group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+, CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of inflammation.

Conclusion: In patients with COPD and BHR, FP has a positive effect on indices of lung function compared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally reduced.

Chronic obstructive pulmonary disease (COPD) is characterised by reduced maximum expiratory flow and slow forced emptying of the lungs. About 15% of smokers develop COPD. The airways are markedly inflamed, but the predominant type of inflammatory cells and the main anatomical site of the lesions appear to differ from those in asthma.8,9 Inhaled corticosteroids are used in the treatment of asthma, but the beneficial effects of steroid treatment in COPD are debatable. Lung function improvement parameters, which are characteristic of steroid treatment in asthma, have not been unequivocally found in patients with COPD.10 It has been postulated that, if steroids are important in the treatment of COPD, they act via downregulation of cytokine and adhesion molecule expression with a consequent reduction in cell migration and activation.9 To date, only a limited number of studies have examined the effect of steroid treatment on inflammation in COPD.

Approximately 25% of patients with stable COPD could, however, benefit from continuous steroid treatment.11 It has been suggested that inhaled corticosteroids are more likely to have beneficial effects in patients with COPD when features of asthma are present.12 It has recently been reported that prednisolone has a beneficial effect in patients with COPD who have increased numbers of sputum eosinophils.13 In a large multicentre trial in patients with respiratory symptoms, the effect of an inhaled steroid on the course of forced expiratory volume in 1 second (FEV1) was found to be most prominent in those with more severe bronchial hyperresponsiveness (BHR).14 BHR is usually seen as a distinguishing characteristic of asthma, but is found surprisingly often in patients with COPD and in smokers.13 The features of BHR, however, differ between asthma and COPD. In COPD the presence of BHR is associated with more severe disease, leading to an even more accelerated decline in lung function (FEV1) resulting in reduced life expectancy.15–18 It could be an indicator of a more serious and/or a different inflammatory process in the airways of these patients with COPD.19–22 A study was therefore undertaken to determine whether patients with COPD and BHR would benefit from treatment with fluticasone propionate (FP), an inhaled steroid.

METHODS

Patients

Twenty-three patients with COPD were selected according to generally accepted criteria (chronic productive cough, FEV1 ≤70% of predicted normal value, FEV1 reversibility of <10% predicted after 750 µg terbutaline administered by metered dose inhalation, negative serological examination (Phadiatop test), and negative skin prick tests for standard inhalled allergens).23 Patients with an FEV1/inspiratory vital capacity (IVC) ratio of <0.70 were also included, provided their total lung capacity (TLC) was greater than the predicted value + 1.64SD. Reference values were obtained from ECGS standards.24 Participants had to be current and persistent smokers aged 40–70 years.

Non-specific BHR was defined as a concentration of histamine provoking a fall in FEV1 of 20% or more (PC_{hista}-40 mg/ml, FEV1 had to be >1.2 l to ensure complete safety in view of the bronchial provocation tests.

The characteristics of the patients are listed in table 1. Subjects were excluded if they had a history of asthma characterised by attacks of dyspnoea, chest tightness or
wheezing, respiratory tract infection in the 4 weeks preceding the first visit, or were suffering from serious or unstable concomitant disease.

Eligible patients using anti-inflammatory treatment including non-steroidal anti-inflammatory drugs were asked to refrain from oral prescriptions for at least 3 months and from inhaled corticosteroids, sodium cromoglycate, or nedocromil sodium for at least 6 weeks before the start of the study. Long acting β₂ agonists, xanthine derivatives, and antihistamine drugs also had to be stopped at least 6 weeks before the start of the study. Patients whose symptoms or lung function deteriorated after discontinuation of drug treatment were excluded from the study.

Six asymptomatic smokers with a normal maximal expiratory flow-volume (MEFV) curve, PC₂₀ histamine >8 mg/ml, and absence of allergy (negative Phadiatop test) served as controls (table 1).

The hospital medical ethics committee approved the study. Written informed consent was obtained from all participants.

**Study design**

The study was double blind and placebo controlled with a treatment period of 6 months. The design is schematically presented in fig 1.

During the 2 week run in period, subjects underwent lung function tests. Eligible patients were randomly allocated to either the treatment group (n=10) who received 500 µg FP twice daily via a Diskhaler, or to the placebo group (n=13) who received their prescription via a similar device. Salbutamol via Diskhaler was given as rescue medication. Inhalation of ipratropium bromide was allowed at a constant dosage. Bronchial biopsy specimens were collected at the start of the treatment period and after 6 months. The participants visited the outpatient clinic every 4 weeks when their used and unused medication from the preceding period was collected from the pneumotachograph readings and PC₂₀ was calculated from these data. Histamine provocation tests were interrupted if a 20% fall in FEV₁ was achieved at a histamine concentration causing 50% of maximal bronchoconstriction, and EC₅₀ (concentration of the stimulus <

<table>
<thead>
<tr>
<th><strong>Table 1</strong> Mean (range) characteristics of study subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
</tr>
<tr>
<td>M/F</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>No cigarettes/day</td>
</tr>
<tr>
<td>Pack years</td>
</tr>
<tr>
<td>Serum IgE (U/l)</td>
</tr>
<tr>
<td>Blood eosinophils (x10⁹/l)</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
</tr>
<tr>
<td>FEV₁ (% predicted)</td>
</tr>
<tr>
<td>Reversibility (% predicted)</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
</tr>
<tr>
<td>PC₂₀ histamine (mg/ml)</td>
</tr>
<tr>
<td>PC₂₀ methacholine (mg/ml)</td>
</tr>
</tbody>
</table>

FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; PC₂₀=concentration provoking a fall in FEV₁ of 20% or more; ND = not done.

*Lp=0.02, †p=0.01 asymptomatic smokers v COPD patients.

‡One patient with FEV₁ of 93% predicted could be included because his FEV₁/FVC was 0.49.

### Lung function tests

Spirometric parameters (total lung capacity (TLC), functional residual capacity (FRC), FVC, FEV₁) were measured at baseline using the closed circuit helium wash-in method. At the start of the study and at each 4 week visit MEFV curves were recorded using a heated pneumotachometer (Jaeger, Wurzberg, Germany). From the MEFV curve the forced vital capacity (FVC), peak expiratory flow (PEF), and maximal expiratory flows at 50% and 25% of FVC (MEF₅₀, MEF₇₅) were derived. All MEFV curves were recorded at the same time of the day. Patients were instructed not to take any bronchodilators for at least 8 hours before lung function tests.

Histamine and methacholine provocation tests were performed using the 2 minute tidal breathing method. Histamine was used to determine PC₂₀ (inclusion criterion), while methacholine was used to establish a full dose-response curve. Solutions of histamine sulphate and acetyl-β-methylcholine bromide were prepared, stored at 4°C, and used at room temperature. Aerosols were generated by a nebuliser (Model 646; DeVilbiss Co, Somerset, PA, USA) (measured output 0.13 ml/min) and inhaled by tidal breathing over a 2 minute period at 5 minute intervals. After inhalation of an isotonic saline solution, doubling concentrations (0.03–256 mg/ml) of histamine or methacholine were administered. The response to methacholine or histamine was measured as the change in FEV₁, expressed as a percentage of the initial value. FEV₁ was derived from the pneumotachograph readings and PC₂₀ was calculated from these data. Histamine provocation tests were interrupted if a 20% fall in FEV₁ was achieved at a histamine concentration of ≤8 mg/ml. Methacholine tests were interrupted if the FEV₁ fell by more than 60%, or if unpleasant side effects occurred. After the test the patient inhaled a bronchodilator to restore the FEV₁ to the initial value.

From the methacholine provocation tests the log₂ concentration and the measured percentage changes in FEV₁ were imported to a computer program that fitted a sigmoid function (cumulative Gaussian distribution) to the data. Reactivity (slope of the curve), plateau values (maximal bronchoconstriction), and EC₅₀ (concentration of the stimulus causing 50% of maximal bronchoconstriction) were taken from this model fit.

After an overnight fast, blood was drawn for measurement of circulating cortisol levels early in the morning before the lung function tests. The concentration of cortisol was determined using kits supplied by Diagnostics Products Corporation (Los Angeles, California, USA).  

### Bronchoscopic examination

The procedure was carried out essentially as described in the ATS guidelines. At the start of the procedure the patient was
given 0.5 mg atropine intramuscularly. A pulse oximeter was applied to a fingertip to monitor pulse rate and oxygen saturation. The mouth and pharynx were anaesthetised with lidocaine spray, and the vocal cords, trachea and bronchial tree were anaesthetised with aerosolised oxybuprocaine solution (5 mg/ml) up to a maximum of 20 ml. Bronchoscopic examination was performed with an Olympus BF 1T10 bronchoscope. At least six biopsy specimens were taken from the subcarinae of both the right and left upper and lower lobes using a fenestrated forceps (FB-18C or FB-20C). Sedative drugs and/or oxygen were administered if needed.

Processing of bronchial biopsy specimens

Bronchial biopsy specimens were snap frozen in tissue-Tek II OCT embedding medium (Miles, Naperville, Illinois, USA) in liquid nitrogen within 10 minutes of collection and stored at –80°C until use. Immunostaining was carried out with coated microscopic slide (Sigma Diagnostics, St Louis, MO, USA) in an air environment. Images were taken at 10 magnification.

Binding of the antibodies was detected by the immunoperoxidase method. Sections were fixed in acetone for 10 minutes at room temperature, rinsed in phosphate buffered saline (PBS), pH 7.2, and placed in a semi-automatic stainer (Shandon, Pittsburgh, PA, USA). The slides were sequentially incubated with 2% bovine serum albumin (BSA) in PBS for 10 minutes, with 10% normal rabbit serum in PBS (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands) for 10 minutes, and then with the appropriate monoclonal antibodies for 60 minutes at room temperature. The sections were then rinsed twice in PBS for 5 minutes and incubated with a rabbit anti-mouse (RdM) (1:50) immunoglobulin serum for 30 minutes. The slides were rinsed twice in PBS, incubated with APAAP (1:50) (Dako, Glostrup, Denmark); α-tryptase (Chemicon Brunschwig Chemie, Temecula, CA, USA); αEG2 (Pharmacia). Immunohistochemical data are presented as the ratio of immunostained area to total area of epithelium or the lamina propria.

Statistical analysis

Results are expressed as mean (SD) unless otherwise indicated. Differences between groups in the effect of treatment and its interaction with time were analysed using the unpaired Student’s t test or the Mann-Whitney U test where appropriate. Paired data were tested for significance with the paired Student’s t test or, after log transformation, the Wilcoxon matched pairs test where appropriate. A rmANOVA was performed for the dependent variables FEV₁ (as percentage predicted), FVC, FEV₁/FVC, PEF, MEF₂₅, and MEF₇₅ after log transformation. From each of these variables, one baseline measurement and six measurements taken during the treatment period were available. The results were adjusted for the baseline measurement of the outcome variable considered. In the rmANOVA model the independent variables were time (as within subject categorical factor with six levels), treatment (as between subjects factor with two levels), and the baseline measurement of the outcome variable considered as a covariate.
between subjects continuous and constant variable. The within subject residual covariance structure is assumed to be of “compound symmetry”. A p value of <0.05 was considered significant.

RESULTS

Patients

Participants in the study had mild to moderate COPD according to ERS criteria and moderately to severe BHR. At baseline there were no significant differences between the FP and placebo groups. Asymptomatic smokers and patients with COPD had significantly different FEV, and FEV/FVC (table 1).

Compliance with study medication was good. The percentage of returned used blister packs did not differ between the groups (92.5% in the FP group and 90.7% in the placebo group).

During the treatment period no subjects dropped out of the study. Periodically, several participants noticed worsening of disease related symptoms such as coughing and production of sputum. In all cases these symptoms could be resolved with rescue medication while not violating the inclusion criteria. Adverse events were reported 25 times in the FP treated group and 28 times in the placebo group (p=0.05). Events relating to airways disease and/or study medication were reported more often by patients receiving placebo than by FP treated patients (18 v 7, p=0.02), and included candidiasis of the mouth (in the FP treated group), stomatitis, throat pain, irritation of the pharynx, upper respiratory tract infection, acute bronchitis without decrease in FEV, and mild increase in airways obstruction.

The use of rescue medication did not differ between the two groups. The mean numbers of salbutamol dosages used in the FP and placebo groups were 32.5 (27.0) and 40.4 (42.7) per month, respectively (p>0.05), and the mean numbers of ipratropium bromide dosages used were 2.2 (4.7) and 9.6 (3.0) per month, respectively.

At the start of the study mean circulating cortisol levels were 360.9 (112) nM/l and 335 (87) nM/l in the FP and placebo groups, respectively. After 6 months the mean levels were 414.6 (156) nM/l and 430 (104) nM/l. The levels were not significantly different between groups at a given time point, nor were they significantly different between time points.

Lung function

During the 6 month treatment period the mean PC20 methacholine increased in the FP treated patients relative to the placebo group (fig 2), but this increase was not statistically significant. No significant changes in reactivity, maximal bronchial constriction (plateau), and EC50 were detected (fig 3). There were no significant treatment x time interactions (table 2); treatment effects were therefore not significantly modified in time so we can assume a treatment effect that was constant throughout time. These treatment effects (FP minus placebo) are presented in table 3.

Changes in mean FEV1, after bronchodilation are shown in fig 4A. A significant decline in FEV1, was seen in the placebo group while FEV1 in the FP treated group remained almost unchanged. The mean decline in FEV1 in the placebo group compared with the FP treated patients was 6.92% predicted before bronchodilation (p=0.027) and 7.97% predicted after bronchodilation (p=0.002). The course of the prebronchodilator and postbronchodilator FEV1 was significantly different between the two treatment groups (p=0.015; postbronchodilator, p=0.0002 (rmANOVA); fig 4B). The starting values were taken as covariants for the rmANOVA tests. The FEV1/FVC ratio (prebronchodilator) showed a similar pattern of change (mean difference 0.065, p=0.024, rmANOVA). There were significant changes in MEF25 from the second month of treatment (0.29 (0.07) l; p=0.002) and in MEF50 from the third month of treatment (0.32 (0.09) l; p=0.008, fig 5A, B). Neither FVC nor PEF were affected and remained unchanged in both groups.

![Figure 4](http://www.thoraxjnl.com)

**Figure 4** [A] Change in forced expiratory volume in 1 second (FEV1), [B] course of mean FEV1, after bronchodilation (both expressed as percentages of predicted normal values), and [C] course of the mean postbronchodilator FEV1 (expressed in litres) during 6 months of treatment with either fluticasone propionate (closed symbols) or placebo (open symbols).
showed neither PC20 nor any other indices of BHR changed as study. Analysis of the methacholine dose-response curves slightly, by the treatment.

Other markers of inflammation were not affected, or only the epithelium were markedly decreased after FP treatment. CD68 were seen in the lamina propria, while tryptase levels in

In the FP treated group substantial reductions in MBP and was markedly decreased in the lamina propria of both groups. The effects of 6 months of treatment with FP or placebo were then analysed (table 5). Compared with the placebo group, FP treatment resulted in only a marginal reduction in the indices of inflammation. Compared with baseline, CD8 was markedly decreased in the lamina propria of both groups. In the FP treated group substantial reductions in MBP and CD68 were seen in the lamina propria, while tryptase levels in the epithelium were markedly decreased after FP treatment. Other markers of inflammation were not affected, or only slightly, by the treatment.

### DISCUSSION

Patients with mild to moderate COPD who were hyperresponsive and who continued smoking were treated with FP (500 µg twice daily) for 6 months in a double blind, placebo controlled study. Analysis of the methacholine dose-response curves showed neither PC20 nor any other indices of BHR changed as a result of FP treatment. We have previously shown that the same dose of FP in patients with asthma with a similar degree of BHR resulted in a rightward shift in the methacholine dose-response curve. Patients with COPD in which PC20 was determined have shown that inhaled steroid treatment had no effect on BHR. To our knowledge, this is the first time that additional indices of BHR (reactivity, plateau, and EC50) have also been shown not to be affected by steroid treatment.

There was, however, a significant reduction in the decline in both prebronchodilator and postbronchodilator FEV1 % predicted (fig 4). Our results are supported by a recent study by Paggiaro et al which showed that treatment of COPD patients with FP (500 µg twice daily for 6 months) resulted in improvement in FEV1 and FVC. The FP treated patients had less frequent and less severe exacerbations. Clinical symptoms improved significantly and sputum production decreased. Markers of inflammation were not analysed.

Treatment for 3 years with inhaled budesonide of subjects with mild COPD who continued smoking in the EUROSCOP study showed an improvement in FEV1 of 17 ml/year compared with a decline of 81 ml/year in the placebo group during the first 6 months of the study. A similar treatment period with FP (ISOLDE) resulted in a significant reduction in the fall in FEV1. The rate of decline in FEV1 in the group that received placebo was markedly higher than that of the steroid treated group over the initial 6 months of treatment, which is comparable with our findings. In contrast, in the Copenhagen City Lung Study long term treatment with inhaled steroids had no effect on decline in lung function in patients with mild to moderate irreversible airflow limitation. In a recent study patients with COPD were treated with triamcinolone for 3 years. A subgroup of the patients was hyperreactive. In this subgroup the rate of decline in lung function did not slow down when evaluated over the entire 3 year study period, but over the initial 6 months triamcinolone had a beneficial effect on the rate of decline in FEV1 compared with placebo. This is in line with our results which showed no decline in FEV1 in the FP treated group while in the placebo group FEV1 decreased significantly. The decline in FEV1, was

### Table 4

Baseline scores of inflammatory markers in epithelium and lamina propria of biopsy specimens taken from the central airways of smoking patients with COPD and healthy smoking control subjects

<table>
<thead>
<tr>
<th>Marker</th>
<th>Patients with COPD</th>
<th>Healthy smoking controls</th>
<th>Patients with COPD</th>
<th>Healthy smoking controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3</td>
<td>0.72 (0.10–4.52)</td>
<td>0.63 (0.24–0.93)</td>
<td>0.36 (0.04–5.71)</td>
<td>0.74 (0.61–1.19)</td>
</tr>
<tr>
<td>CD4</td>
<td>1.07 (1.14–4.00)</td>
<td>0.94 (0.40–2.00)</td>
<td>0.74 (0.07–9.00)</td>
<td>0.64 (0.27–1.63)</td>
</tr>
<tr>
<td>CD8</td>
<td>0.08 (0.03–0.60)</td>
<td>0.05 (0.02–0.09)</td>
<td>0.04 (0.03–0.42)</td>
<td>0.04 (0.01–0.13)</td>
</tr>
<tr>
<td>CD25</td>
<td>0.22 (0.03–3.28)</td>
<td>0.10 (0.03–0.22)</td>
<td>0.15 (0.03–2.39)</td>
<td>0.12 (0.04–2.62)</td>
</tr>
<tr>
<td>MBP</td>
<td>0.12 (0.03–5.27)</td>
<td>0.03 (0.01–0.67)</td>
<td>0.38 (0.00–6.45)</td>
<td>0.25 (0.01–5.13)</td>
</tr>
<tr>
<td>CD15</td>
<td>0.12 (0.01–1.79)</td>
<td>0.12 (0.01–0.55)</td>
<td>0.25 (0.03–0.68)</td>
<td>0.46 (0.14–8.01)</td>
</tr>
<tr>
<td>CD68</td>
<td>3.43 (0.08–17.4)</td>
<td>3.39 (0.68–8.96)</td>
<td>0.62 (0.14–4.73)</td>
<td>0.81 (0.01–1.40)</td>
</tr>
<tr>
<td>CD1a</td>
<td>1.53 (0.24–11.4)</td>
<td>1.09 (0.46–1.98)</td>
<td>2.49 (0.44–20.10)</td>
<td>2.95 (1.13–4.74)</td>
</tr>
<tr>
<td>Tryptase</td>
<td>0.12 (0.03–0.45)</td>
<td>0.08 (0.03–0.18)</td>
<td>0.14 (0.04–0.35)</td>
<td>0.07 (0.02–0.12)</td>
</tr>
</tbody>
</table>

Data are expressed as median (range) ratios of immunostained areas and field measurement which consisted of the total area of either the epithelium or the lamina propria. Statistical analysis by Mann-Whitney U test after log transformation.
Steroid treatment should have been achieved during this time. Other studies including EUROSCOP, the effects of inhaled short-acting steroids are in the smaller airways. Significant changes in expiratory flow, the significance and consistency of this finding, in COPD causing a degree of eosinophilic airway inflammation. Eosinophils are important in the inflammatory process. Although MEF50 and MEF25 are less accurate parameters of airway function, the significance and consistency of this finding, in COPD preventing a decline in FEV1 and keeping it constant. Fluticasone propionate in COPD with bronchial hyperresponsiveness.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Fluticasone propionate</th>
<th>Placebo</th>
<th>Fluticasone propionate</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3</td>
<td>0.57 (0.10–4.52)</td>
<td>0.28 (0.10–1.54)</td>
<td>0.79 (0.35–2.23)</td>
<td>0.45 (0.15–3.25)</td>
</tr>
<tr>
<td>CD4</td>
<td>1.03 (0.40–4.00)</td>
<td>0.70 (0.40–2.03)</td>
<td>1.11 (0.19–1.79)</td>
<td>1.19 (0.70–2.17)</td>
</tr>
<tr>
<td>CD8</td>
<td>0.09 (0.05–0.60)</td>
<td>0.09 (0.01–0.12)</td>
<td>0.09 (0.03–0.26)</td>
<td>0.09 (0.03–0.23)</td>
</tr>
<tr>
<td>CD25</td>
<td>0.09 (0.07–3.28)</td>
<td>0.20 (0.03–0.31)</td>
<td>0.27 (0.03–0.32)</td>
<td>0.15 (0.00–0.15)</td>
</tr>
<tr>
<td>MIP2</td>
<td>0.06 (0.01–1.22)</td>
<td>0.03 (0.01–0.25)</td>
<td>0.15 (0.03–0.32)</td>
<td>0.10 (0.00–0.10)</td>
</tr>
<tr>
<td>EG2</td>
<td>0.16 (0.01–0.45)</td>
<td>0.06 (0.02–0.31)</td>
<td>0.08 (0.03–0.37)</td>
<td>0.07 (0.01–0.47)</td>
</tr>
<tr>
<td>CD15</td>
<td>3.31 (1.52–17.4)</td>
<td>1.12 (0.08–8.68)</td>
<td>4.32 (0.15–14.6)</td>
<td>1.64 (0.53–27.70)</td>
</tr>
<tr>
<td>CD68</td>
<td>1.42 (0.24–11.4)</td>
<td>0.81 (0.23–2.64)</td>
<td>1.64 (0.29–9.86)</td>
<td>1.19 (0.37–15.12)</td>
</tr>
<tr>
<td>CD1a</td>
<td>0.14 (0.00–0.45)</td>
<td>0.13 (0.05–0.29)</td>
<td>0.10 (0.05–0.30)</td>
<td>0.10 (0.01–0.09)</td>
</tr>
<tr>
<td>Tryptase</td>
<td>0.10 (0.05–63)</td>
<td>0.02 (0.00–18)</td>
<td>0.18 (0.03–0.61)</td>
<td>0.10 (0.02–0.59)</td>
</tr>
</tbody>
</table>

Data are expressed as median [range] ratios of immunostained areas and field measurement which consisted of the total area of either the epithelium or the subepithelium. Statistical analysis by paired Wilcoxon test after log transformation.

ACKNOWLEDGEMENT

The authors thank GlaxoWellcome (FLIL44/FMS40060), Zest, The Netherlands for providing study medication and financial support.

Authors' affiliations

G T Verhoeven, J P J J Hegmans, J M Bogaard, H C Hoogsteden, J-B Prins, Department of Pulmonary and Intensive Care Medicine, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
P G H Mulder, Department of Biostatistics, Erasmus Medical Center, Rotterdam

REFERENCES


Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

G T Verhoeven, J P J Hegmans, P G H Mulder, J M Bogaard, H C Hoogsteden and J-B Prins

Thorax 2002 57: 694-700
do: 10.1136/thorax.57.8.694

Updated information and services can be found at:
http://thorax.bmj.com/content/57/8/694

These include:

References

This article cites 36 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/57/8/694#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Inflammation (1020)
- Asthma (1782)
- Health education (1223)
- Smoking (1037)
- Tobacco use (1039)
- Airway biology (1100)
- Drugs: respiratory system (526)
- Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/